Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosed with B-CLL/SLL based on the standard histologic and immunophenotypic criteria described in the WHO classification~* No prior systemic therapy for CLL/SLL, including chemotherapy or antibody therapy~* Currently needs therapy based on 1996 NCI-WG criteria~* Measurable disease~* ECOG Performance Status of 0-2~* Laboratory test results within parameters outlined in protocol~* Able to take aspirin daily as prophylactic anticoagulation~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent document~* Pregnant or breast-feeding females~* Any condition, including the presence of abnormal laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~* Use of any other experimental drug or therapy within 28 days of baseline~* Known hypersensitivity to thalidomide~* Development of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs~* Prior use of lenalidomide~* Concurrent use of other anti-cancer agents or treatments~* Known positive for HIV~* Chronic active Hep B patients not on prophylactic lamivudine~* Diagnosis of Mantle Cell Lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide, fludarabine and rituximab (Type: EXPERIMENTAL): Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).